Materialise (MTLS) investor relations material

Executive summary

• Q2 2026 revenue rose 8.1% year-over-year to EUR 70.1 million, with H1 2026 revenue up 3.9% to EUR 136.3 million; net profit for Q2 was EUR 3.3 million or EUR 0.06 per share.

• Profitability scaled faster than revenue, with adjusted EBIT at EUR 3.9 million (5.5% margin) and net cash position increasing to EUR 74.2 million.

• Strategic divestments of RapidFit and Eyewear sharpened portfolio focus, with a 20% minority stake retained in Eyewear and a EUR 0.7 million asset impairment.

• Strengthened leadership team with new CHRO and Chief Digital and Information Officer appointments; EVP Medical departed.

• Launched new CO-AM software offerings and invested in Replasia to expand personalized hip care portfolio.

Financial highlights

• Q2 2026 consolidated revenue: EUR 70.1 million (+8.1% YoY); H1 2026 revenue: EUR 136.3 million (+3.9% YoY).

• Q2 gross profit: EUR 39.8 million (56.8% margin); adjusted EBITDA: EUR 9.6 million (+15.7% YoY, 13.7% margin); adjusted EBIT: EUR 3.9 million (5.5% margin).

• Net cash position at June 30, 2026: EUR 74.2 million; cash reserves at EUR 133.7 million; gross debt reduced to EUR 59.5 million.

• Share buyback program invested EUR 5.2 million in H1 2026, acquiring 1.1 million ADSs (1.8% of share base).

• Free cash flow for H1: EUR 11.4 million, nearly double the prior year.

Outlook and guidance

• Full-year 2026 revenue guidance reaffirmed at EUR 273–283 million, absorbing divestment impacts.

• Full-year adjusted EBIT guidance raised to EUR 12–14 million (from EUR 10–12 million), reflecting strong execution and cost discipline.

• Medical segment expected to sustain around 10% annual growth, with quarter-to-quarter fluctuations.

• Management expects continued profitable growth and disciplined cost management.